Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Optimising therapy for EGFR-addicted NSCLC: just the start.

The Lancet. Oncology - 1 Mar 2012

Govindan Ramaswamy, Subramanian Janakiraman

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Combined Chemotherapy Protocols
Share to Carcinoma, Non-Small-Cell Lung
Share to ErbB Receptors
Share to Erlotinib Hydrochloride

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Lung Neoplasms

Share to Mutation

Share to Protein Kinase Inhibitors

Share to Quinazolines

Source

Identifiers

PMID: 22285167
DOI: 10.1016/S1470-2045(12)70037-2

Genes

EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Optimising therapy for EGFR-addicted NSCLC: just the start.PMID 22285167Read ↗

LUX-Lung: determining the best EGFR inhibitor in NSCLC?Semantic proximity Read ↗

Lung adenocarcinoma: guiding EGFR-targeted therapy and beyond.Semantic proximity Read ↗

New Treatment Options for Patients With Oncogene-Addicted Non-Small Cell Lung Cancer Focusing on EGFR-Mutant Tumors.Semantic proximity Read ↗

Management of Resistance to EGFR TKI-Targeted Therapy of Lung Cancer: Lessons in Monitoring Cancer Evolution.Semantic proximity Read ↗

Updates in the Management of EGFR-Mutated Non-small Cell Lung Cancer (NSCLC).Semantic proximity Read ↗

Optimal Therapy for Advanced Non-Small Cell Lung Cancer Without Driver Alterations.Semantic proximity Read ↗

Personalized care for patients with EGFR-mutant nonsmall cell lung cancer: Navigating early to advanced disease management.Semantic proximity Read ↗

Targeted therapeutic options in early and metastatic NSCLC-overview.Semantic proximity Read ↗

Lung cancer in 2014: optimizing lung cancer treatment approaches.Semantic proximity Read ↗

EGFR mutation-positive NSCLC: factors to consider when deciding first-line therapy.Semantic proximity Read ↗

Pharmacotherapy targeting the EGFR oncogene in NSCLC.Semantic proximity Read ↗

Navigating the "No Man's Land" of TKI-Failed EGFR-Mutated Non-Small Cell Lung Cancer (NSCLC): A Review.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.